| Autor: |
Ranjan, Simona, Mohan, Nitesh, Arya, Anjana, Bisht, Mithila |
| Předmět: |
|
| Zdroj: |
Journal of Cardiovascular Disease Research (Journal of Cardiovascular Disease Research); 2024, Vol. 15 Issue 8, p1488-1496, 9p |
| Abstrakt: |
Background: Cervical malignancy is a serious global public health issue that affects women and major cause of death in low and middle-income nations. Even when using cisplatin-based combination therapy, individuals with severe or recurring illness have a poor prognosis, Therefore, there is a growing need to identify new therapeutic targets that can supplement or replace the present treatment for these individuals. Objectives: To study the expression of HER-2/neu biomarker in premalignant and malignant epithelial lesions of uterine cervix and its correlation with general clinical parameters and histological type, grade, and tumor stage. Material and methods: A cross-sectional study was conducted on 72 histologically diagnosed cases of premalignant and malignant epithelial lesions of uterine cervix in 1 year. Detailed gross and microscopic examination followed by HER-2/neu immunostaining was performed in all cases. Results: Out of 72 cases of cervical lesions, premalignant were 9 in number whereas 63 cases were malignant. HER-2/neu expression was noted in 21 cases (29.2 %) out of 72 cases. Higher HER-2/neu expression intensity (2+ and 3+) was seen in malignant lesions (17.5 %, n=11) than in premalignant lesions (11.1 %, n=1). In comparison to well-differentiated SCC (n=2), the percentage of lesions with higher expression (2+ and 3+ scores) was considerably higher in poorly and moderately differentiated groups (n=8). HER-2/neu expression intensity increases with the advancement of clinical stage of malignant cervical lesions. Conclusion: Over-expression of HER-2/neu biomarker is associated with poor prognosis and aggressive behavior of premalignant and malignant cervical lesions. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
